KMX vs NKTR · P/E 19, rev $25.88B vs rev $21.0M
CarMax Inc (KMX) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
CarMax Inc (KMX) is a auto & truck dealerships company listed on US.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported KMX revenue for 2026-02-28 was $25.88B. Net income was $247.3M. Revenue was down 1.8% from 2025-02-28 to 2026-02-28. KMX currently screens at market cap $10.26B and trailing P/E 18.9.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
KMX currently screens at market cap $10.26B and trailing P/E 18.9. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the KMX and NKTR stock pages for the full models.
Not investment advice.